Prometrium Dose Conversion: Weekly to Daily Dosing Explained

What Does "Dose Conversion Weekly to Daily" Actually Mean for Prometrium?

When clinicians talk about converting Prometrium from weekly to daily dosing, they are usually describing a shift from a cyclic or sequential schedule to a continuous one. In cyclic hormone therapy, you take Prometrium for a defined block of days each month, typically 12 to 14 days, then stop. In continuous therapy, you take a lower dose every single night without a break.

These are not interchangeable by simple arithmetic. The total monthly milligram load differs, the hormonal exposure pattern differs, and the clinical goals differ. Understanding why your dose or schedule is being changed matters as much as knowing what to take.

The Two Standard Schedules

The FDA-approved Prometrium prescribing information describes two primary regimens for women with a uterus who are also taking conjugated estrogen:

• Cyclic (sequential) regimen: 200 mg orally each night at bedtime for 12 consecutive days per 28-day cycle.
• Continuous regimen: 100 mg orally each night at bedtime every day without a scheduled break.

Both regimens are designed to protect the uterine lining from unopposed estrogen stimulation. Unopposed estrogen in a woman with a uterus increases endometrial cancer risk; adequate progestogen coverage is not optional.

Why the Doses Are Not Simply Halved

A 12-day course of 200 mg delivers 2,400 mg of progesterone per cycle. A 28-day continuous course of 100 mg delivers 2,800 mg. The monthly totals are similar but not identical, and the pattern of hormonal exposure matters biologically. Continuous lower-dose progesterone produces steadier serum levels, which tends to reduce withdrawal bleeding. Cyclic higher-dose progesterone produces a defined hormonal peak and withdrawal, which is why most women on a cyclic regimen experience a monthly bleed.

How Micronized Progesterone Behaves in Your Body

Micronized progesterone (the active ingredient in Prometrium) is absorbed through the gut, but oral bioavailability is low, roughly 10 percent due to extensive first-pass hepatic metabolism. This is a key physiological fact that shapes both dosing and scheduling decisions for women.

Pharmacokinetics Specific to Women

Peak serum progesterone concentration (Cmax) after a 200 mg oral dose occurs at approximately 3 hours and then falls sharply. Because of this rapid rise and fall, Prometrium produces higher peak sedation than equivalent progestogen exposure from a transdermal or vaginal route. Taking your dose at bedtime is a clinical strategy, not an arbitrary instruction. The sedative effect (mediated partly through progesterone's metabolite allopregnanolone acting on GABA-A receptors) can actually improve sleep quality in perimenopausal women, which is a meaningful secondary benefit.

Hormonal Status Changes Drug Behavior

Progesterone pharmacokinetics are not static across your reproductive life:

• Reproductive years: Endogenous progesterone peaks at 10 to 35 ng/mL in the luteal phase. Exogenous Prometrium at 100 mg adds roughly 2 to 10 ng/mL on top of that, so the combined level matters for women taking it for luteal phase support or PCOS management.
• Perimenopause: Endogenous progesterone output is erratic and often low. Anovulatory cycles become increasingly common in the 2 to 8 years before the final menstrual period, meaning many perimenopausal women have minimal baseline progesterone and respond more predictably to exogenous doses.
• Post-menopause: Endogenous progesterone is essentially zero. The prescribed dose is the total dose. This simplifies titration but makes endometrial protection entirely dependent on adherence.

The Clinical Rationale for Switching Schedules

Your prescriber may recommend converting from cyclic to continuous (or the reverse) for several reasons. None of these is one-size-fits-all.

Reasons to Move from Cyclic to Continuous Dosing

• Eliminating monthly withdrawal bleeding. Most post-menopausal women starting hormone therapy prefer not to resume a monthly bleed. Continuous combined therapy (daily estrogen plus daily low-dose progesterone) produces amenorrhea in approximately 80 to 90 percent of women after 12 months, though irregular spotting is common in the first 3 to 6 months.
• Simplifying adherence. A daily routine is often easier to maintain than a 12-days-on, 16-days-off schedule.
• Managing endometrial risk in women who forget cyclic courses. Missing days of a cyclic progestogen course leaves the endometrium incompletely opposed. Continuous dosing reduces the consequence of occasional missed doses.

Reasons to Stay on or Return to Cyclic Dosing

• Perimenopausal women who still want cycle regularity. Women in perimenopause who are not yet ready for amenorrhea sometimes prefer the predictable withdrawal bleed of a cyclic schedule, which can feel more reassuring than unpredictable spotting.
• Women closer to the menopause transition. The NAMS 2022 Hormone Therapy Position Statement notes that cyclic combined regimens are often preferred in early perimenopause to mimic natural cycle physiology.
• Endometrial monitoring concerns. Some clinicians prefer the cleaner endometrial shedding pattern of cyclic therapy to reduce the chance of undetected endometrial pathology.

Life-Stage Guide to Prometrium Dosing

Perimenopause

In perimenopause, your ovaries still produce estrogen erratically but progesterone output is inconsistent. If you are taking systemic estrogen to manage hot flashes, night sweats, or sleep disruption, you need progestogen coverage if you have a uterus.

A cyclic schedule of 200 mg nightly for 12 to 14 days per month is the standard starting point for perimenopausal women because it works with the remaining cycle architecture. As you move further from your last period, your clinician may propose a switch to 100 mg continuous.

The ACOG Practice Bulletin on Management of Menopausal Symptoms (Number 141, reaffirmed 2022) supports progestogen use in all women with a uterus who use systemic estrogen therapy.

Post-Menopause

Once you are confirmed post-menopausal (12 consecutive months without a period), the continuous 100 mg nightly regimen becomes the dominant approach in most guidelines. This is the dose and schedule studied in the PEPI Trial (Postmenopausal Estrogen/Progestin Interventions), the landmark 1995 RCT that established micronized progesterone's favorable lipid profile compared to medroxyprogesterone acetate in post-menopausal women.

The PEPI trial enrolled 875 post-menopausal women and found that conjugated equine estrogen plus cyclic micronized progesterone 200 mg for 12 days produced HDL cholesterol increases closest to estrogen-alone among all the combination regimens tested, a sex-specific cardiovascular signal that still influences prescribing preferences today.

PCOS Across the Reproductive Years

Women with polycystic ovary syndrome frequently have chronic anovulation, meaning progesterone production from the corpus luteum does not occur. Prometrium is sometimes prescribed to induce a withdrawal bleed every 1 to 3 months, protecting the endometrium from the effects of unopposed estrogen produced by peripheral aromatization.

This is a different clinical goal from hormone therapy, and the dosing reflects that: typically 200 mg nightly for 10 to 14 days to provoke shedding, not a daily continuous schedule. If you have PCOS and your clinician is suggesting a dose conversion, clarify whether the goal is cycle induction or endometrial protection in the context of hormonal treatment.

Trying to Conceive and Luteal Phase Support

Prometrium is widely used off-label for luteal phase support in assisted reproductive cycles. Doses in this context range from 200 mg to 600 mg daily (divided or single dose), typically vaginally rather than orally, because vaginal administration bypasses first-pass metabolism and achieves higher endometrial tissue concentrations at lower systemic doses. If you are converting from oral to vaginal Prometrium for a fertility cycle, the dose equivalency changes substantially and your reproductive endocrinologist should direct this adjustment specifically.

Practical Conversion: From Cyclic to Daily in Hormone Therapy

This framework is designed to translate the FDA label and clinical trial data into a decision-structured approach women can use in conversation with their prescriber. It does not replace individualized medical advice.

Step 1: Confirm your uterine status. If you have had a hysterectomy, you do not need progesterone for endometrial protection. Women without a uterus who are taking progesterone for sleep, mood, or other off-label reasons are in a different clinical category, and dose conversion logic differs.

Step 2: Identify your goal for the switch. Is the goal to stop monthly bleeding? Simplify adherence? Reduce side effects? Each goal may point to a different adjustment strategy.

Step 3: Use the established dose anchors.

| Schedule | Dose | Days per Month | Expected Bleeding Pattern | |---|---|---|---| | Cyclic | 200 mg nightly | 12 days | Withdrawal bleed after course ends | | Continuous | 100 mg nightly | 28 days | Amenorrhea after 6-12 months | | Transitional | 100 mg nightly | 28 days for first 3-6 months | Irregular spotting, then amenorrhea |

Step 4: Allow an adjustment window. Irregular spotting for 3 to 6 months after switching to continuous therapy is expected and does not indicate treatment failure or endometrial pathology. Bleeding that is heavy, prolonged beyond 6 months, or occurs after a period of amenorrhea warrants endometrial evaluation.

Step 5: Recheck at 3 months. A brief symptom check at 3 months helps confirm that endometrial protection is adequate, side effects are tolerable, and the new schedule fits your daily routine.

Side Effects and How They Change With Schedule

Prometrium's side effects are dose-dependent and route-dependent. Women commonly report:

• Sedation and dizziness (most common with 200 mg oral dose, less common at 100 mg)
• Breast tenderness (can intensify in the first cycle of a new schedule)
• Mood changes (some women report improved mood and less anxiety on micronized progesterone compared to synthetic progestins; this is attributed to allopregnanolone's anxiolytic properties)
• Bloating and GI upset (taking with a small snack, not a full meal, can reduce variability in absorption)

Switching from cyclic 200 mg to continuous 100 mg often reduces sedation because the peak serum concentration is lower. Women who report feeling "groggy" the morning after their cyclic dose frequently find the lower continuous dose more manageable.

A 2012 observational study in Menopause found that women using micronized progesterone reported better sleep quality and mood scores than women using medroxyprogesterone acetate at equivalent endometrial-protective doses, a finding that matters when you are deciding whether to stay on a schedule or request an adjustment.

Pregnancy, Lactation, and Contraception: What Every Woman Must Know

This section is required for any drug article on WomanRx, because the answers are specific, consequential, and frequently misunderstood.

Pregnancy

The FDA removed letter-based pregnancy categories in 2015 and replaced them with narrative labeling. The current Prometrium prescribing label carries the following clinically critical points:

• Prometrium is not approved for use in early pregnancy in its oral capsule formulation. The label explicitly states it should not be used in women with a history of or current thrombophlebic disorders, and it carries a warning related to use in missed abortion.
• Progesterone supplementation in early pregnancy is a separate clinical indication, typically managed with vaginal or injectable progesterone under reproductive endocrinology supervision, not oral Prometrium capsules.
• Women of reproductive age taking Prometrium as part of hormone therapy for perimenopause should use reliable contraception until confirmed post-menopausal, because hormone therapy does not prevent ovulation and therefore does not prevent pregnancy.

If you become pregnant while taking Prometrium, contact your prescriber immediately. Do not stop or change your dose without guidance.

Lactation

Progesterone is detectable in breast milk. Animal and limited human data suggest transfer occurs, though the clinical significance for a nursing infant is not fully established. The LactMed database (NIH) recommends caution and notes that the long-term effects on a breastfed infant from exogenous maternal progesterone are not well characterized.

Women who are postpartum and breastfeeding and who are being prescribed Prometrium for reasons such as postpartum mood stabilization or cycle regulation should discuss the risk-benefit balance explicitly with their prescriber.

Contraception Note

Prometrium at hormone-therapy doses does not provide contraceptive protection. If you are perimenopausal and still ovulating, even occasionally, you need a separate contraceptive method if pregnancy is not desired. The ACOG Committee Opinion on Hormonal Contraception in Women of Reproductive Age is clear that hormone therapy and hormonal contraception serve distinct purposes and should not be conflated.

Who This Is Right For and Who Should Reconsider

Women for Whom Daily Continuous Prometrium Is a Good Fit

• Post-menopausal women on systemic estrogen who prefer amenorrhea
• Women who find the cyclic schedule difficult to remember or manage
• Women who experience significant sedation from the 200 mg cyclic dose and do better on the lower nightly 100 mg
• Women whose endometrial biopsy or ultrasound shows adequate protection on continuous dosing at follow-up

Women Who May Do Better on a Cyclic Schedule

• Perimenopausal women who are <2 years from their last period and still have some natural cycle activity
• Women who find the irregular spotting of the continuous regimen more distressing than a predictable monthly bleed
• Women in whom a defined withdrawal bleed serves as a reassurance that the uterus is shedding appropriately

Women Who Need a Different Conversation Entirely

• Women without a uterus (no progestogen needed for endometrial protection; any use is off-label)
• Women with progesterone-sensitive conditions such as certain meningiomas or breast cancers who should review all progesterone use with their oncologist or neuro-oncologist
• Women with known peanut allergy (Prometrium capsules contain peanut oil and are contraindicated in this group per the FDA label)

The evidence gap is real here. Most RCT data on micronized progesterone dose conversion comes from post-menopausal populations. Data on optimal conversion strategies in perimenopausal women, women with PCOS, and women in the postpartum period are largely extrapolated from case series, observational studies, and expert consensus rather than randomized controlled trials. Your clinician is calibrating dose based on limited direct evidence in many of these situations, and that transparency matters.

Monitoring After a Dose Conversion

Switching Prometrium schedules is not a set-and-forget adjustment. The following monitoring approach reflects standard clinical practice:

• Baseline and 3-month uterine symptom check: Report any unexpected bleeding, spotting, or pelvic pressure.
• Annual endometrial assessment consideration: Women on long-term estrogen-progestogen therapy with persistent or returning bleeding after a period of amenorrhea should be evaluated with transvaginal ultrasound and, if the endometrial stripe exceeds 4 mm in post-menopause, an endometrial biopsy.
• Breast tissue awareness: Combined estrogen-progestogen therapy for more than 3 to 5 years is associated with a small but measurable increase in breast cancer risk. The Women's Health Initiative (WHI) combined arm used medroxyprogesterone acetate, not micronized progesterone; observational data including the E3N cohort study suggest micronized progesterone may carry a lower breast cancer risk than synthetic progestins, though this requires confirmation in RCTs and should not be used to justify indefinite use without reassessment.
• Lipid panel at 6 to 12 months: Progestogen type and dose can influence lipid profiles. Micronized progesterone is generally considered lipid-neutral compared to medroxyprogesterone acetate, consistent with the PEPI trial findings.

If your clinician has not mentioned follow-up after your dose conversion, ask specifically when your next endometrial or symptom check is scheduled and what bleeding pattern should prompt you to call sooner.